MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Akciju saraksts・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Slēgts

SektorsVeselības aprūpe

24.52 -2.54

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

24.31

Max

Galvenie mērījumi
By Trading Economics
Ienākumi	51M -129M
Pārdošana	207M
Peļņas marža	-62.319
Darbinieki	1,371
EBITDA	8.8M -105M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+105.8% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	344M 2.3B
Iepriekšējā atvēršanas cena	27.06
Iepriekšējā slēgšanas cena	24.52

Ziņu noskaņojums

By Acuity

67%

33%

315 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

32.76 / 39.24 Atbalsts un pretestība

Ultragenyx Pharmaceutical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 16. apr. 23:26 UTC

Karstas akcijas

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

2026. g. 16. apr. 20:41 UTC

Galvenie tirgus virzītāji

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

2026. g. 16. apr. 23:49 UTC

Tirgus saruna

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

2026. g. 16. apr. 23:45 UTC

Tirgus saruna

Nikkei May Decline After Hitting Record High -- Market Talk

2026. g. 16. apr. 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

2026. g. 16. apr. 22:51 UTC

Tirgus saruna

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

2026. g. 16. apr. 22:08 UTC

Peļņas

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

2026. g. 16. apr. 22:06 UTC

Peļņas

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

2026. g. 16. apr. 22:06 UTC

Peļņas

Lundin Mining: Pre-Announces Items Impacting 1Q Results

2026. g. 16. apr. 22:06 UTC

Peļņas

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

2026. g. 16. apr. 22:06 UTC

Peļņas

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

2026. g. 16. apr. 22:06 UTC

Peļņas

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

2026. g. 16. apr. 20:50 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 16. apr. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 16. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 16. apr. 20:50 UTC

Tirgus saruna

Peļņas

Health Care Roundup: Market Talk

2026. g. 16. apr. 20:49 UTC

Peļņas

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

2026. g. 16. apr. 20:43 UTC

Peļņas

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

2026. g. 16. apr. 20:40 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2026. g. 16. apr. 20:40 UTC

Tirgus saruna

Peļņas

Netflix Says Engagement Quality Hits New High -- Market Talk

2026. g. 16. apr. 20:30 UTC

Karstas akcijas

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

2026. g. 16. apr. 20:25 UTC

Peļņas

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

2026. g. 16. apr. 20:23 UTC

Peļņas

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

2026. g. 16. apr. 20:19 UTC

Peļņas

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

2026. g. 16. apr. 20:17 UTC

Peļņas

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

2026. g. 16. apr. 20:17 UTC

Peļņas

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

2026. g. 16. apr. 20:16 UTC

Peļņas

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

2026. g. 16. apr. 20:16 UTC

Peļņas

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

2026. g. 16. apr. 20:16 UTC

Peļņas

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

2026. g. 16. apr. 20:16 UTC

Peļņas

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Salīdzinājums

Cenas izmaiņa

Ultragenyx Pharmaceutical Inc Prognoze

Cenas mērķis

By TipRanks

105.8% augšup

Prognoze 12 mēnešiem

Vidējais 51.82 USD 105.8%

Augstākais 84 USD

Zemākais 25 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ultragenyx Pharmaceutical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

18 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 18 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ultragenyx Pharmaceutical Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

32.76 / 39.24Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Noskaņojums

By Acuity

315 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.